Precursor-B Acute Lymphoblastic Leukemia
Pre-B ALL is the most common malignancy in childhood with an overall cure rate of approximately 85%. However, relapsed ALL have an event-free survival of only 47%. CAR-T cells were shown efficient in ALL, but as much as 30 to 60% of patients relapse mainly because of the lack of CAR-T cells persistence or antigen loss (CD19).
Also, CRS occurs in 75% to 100% of children treated by CAR-T cells, with between 16% to 46% of patient needing hospitalisation. There is, therefore, a dire need to improve CAR-therapy for children with ALL.